top of page

Evonik Shows Strong Growth in Q3 2026

ial
15 minutes ago
2 min read

Evonik Industries reported strong financial results in the third quarter of 2026, with adjusted EBITDA increasing by 40% year-on-year to €629 million, despite subdued economic growth and ongoing geopolitical tensions.


The performance was supported by higher sales volumes, improved selling prices and efficiency initiatives across its businesses. Based on the strong results, Evonik expects its full-year 2026 adjusted EBITDA to reach the upper half of its guidance range of €2.0–2.2 billion.


Evonik Q3 Results

Group sales increased by 13% year-on-year, marking the strongest quarterly growth since Q3 2022. Sales volumes rose by 2%, while selling prices increased by 10%. Free cash flow also improved to €369 million, compared with €300 million in the corresponding period of 2025. For the first nine months of 2026, free cash flow more than doubled to €601 million, supporting the company's debt-reduction efforts.


Evonik's Advanced Technologies segment delivered particularly strong results, with sales increasing by 19% to €1,713 million and adjusted EBITDA rising by 87% to €377 million.


Growth was supported by higher demand and selling prices in animal nutrition, improved performance in crosslinkers and high-performance polymers, and stronger demand for precipitated silicas. The segment's adjusted EBITDA margin increased to 22.0%, compared with 14.0% in Q3 2025.


The Custom Solutions segment recorded a 4% increase in sales to €1,394 million, while adjusted EBITDA rose by 7% to €231 million. Higher selling prices, particularly in the additives business, helped offset increased raw material costs. Demand for additives used in paints and coatings and oil applications remained positive, while sales of polyurethane foam additives and consumer durables products remained broadly stable. The segment's EBITDA margin improved to 16.6% from 16.0% a year earlier.


Alongside its operational performance, Evonik is continuing its cost-reduction and portfolio optimisation strategy. Its Evonik Tailor Made (ETM) efficiency programme has been extended until 2029, with €313 million allocated for related measures during the third quarter. The company is also progressing with the planned sale of its Oxeno C4 chemistry business, while preparations have begun for a potential sale of Syneqt, which operates chemical parks in Marl and Wesseling, Germany.

Evonik expects fourth-quarter earnings to improve compared with the same period last year. The company is targeting a cash conversion rate of approximately 40% and free cash flow of around €850 million for 2026. It also expects return on capital employed (ROCE) to exceed 8% in 2026, moving towards its medium-term target of approximately 11% by 2029.


Source: Evonik

Contact Us

​

Tel: +44 20 8832 7780

ial@brggroup.com

  • LinkedIn Social Icon

© Copyright 2026, BRG Enterprise Solutions Ltd. All Rights Reserved.

bottom of page